162 related articles for article (PubMed ID: 2525400)
1. Anthracycline-induced toxicity affecting palmar and plantar skin.
Jones AP; Crawford SM
Br J Cancer; 1989 May; 59(5):814. PubMed ID: 2525400
[No Abstract] [Full Text] [Related]
2. Palmar-plantar erythrodysaesthesia and non-pegylated liposomal doxorubicin. A case study.
Tamayo-Orbegozo E; Iruin-Sanz A; Oñate-Muzás E; Segrelles-Bellmunt G
Farm Hosp; 2011; 35(1):46-7. PubMed ID: 20619714
[No Abstract] [Full Text] [Related]
3. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Risum S; Langer SW
Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
[TBL] [Abstract][Full Text] [Related]
4. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced palmer planter erythrodysesthesia.
Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
[TBL] [Abstract][Full Text] [Related]
6. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
[TBL] [Abstract][Full Text] [Related]
7. Images in clinical medicine. Chemotherapy-induced acral erythema.
Pirisi M; Soardo G
N Engl J Med; 1994 May; 330(18):1279. PubMed ID: 8145783
[No Abstract] [Full Text] [Related]
8. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Markman M; Kulp B; Peterson G
Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis in oncology. Hand-foot syndrome.
Jucgla A; Sais G
J Clin Oncol; 1997 Sep; 15(9):3164. PubMed ID: 9312563
[No Abstract] [Full Text] [Related]
10. Acute and painful erythema of the hands and feet. Acral erythema induced by chemotherapy.
Revenga Arranz F; Fernández-Durán DA; Grande C; Rodríguez Peralto JL; Vanaclocha Sebastián F
Arch Dermatol; 1997 Apr; 133(4):499-500, 502-3. PubMed ID: 9126025
[No Abstract] [Full Text] [Related]
11. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
Tomb R; Stephan F; Halaby G
Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
[No Abstract] [Full Text] [Related]
12. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur.
Jucglà A; Sais G; Navarro M; Peyri J
Arch Dermatol; 1995 Mar; 131(3):364-5. PubMed ID: 7887678
[No Abstract] [Full Text] [Related]
13. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
14. Hand-foot syndrome.
Pike K
Oncol Nurs Forum; 2001; 28(10):1519-20. PubMed ID: 11759299
[No Abstract] [Full Text] [Related]
15. Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy.
Cox GJ; Robertson DB
Arch Dermatol; 1986 Dec; 122(12):1413-4. PubMed ID: 2947543
[TBL] [Abstract][Full Text] [Related]
16. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
17. Palmar-plantar erythema associated with combination chemotherapy.
Pagliuca A; Kaczmarski R; Mufti GJ
Postgrad Med J; 1990 Mar; 66(773):242-3. PubMed ID: 1694580
[TBL] [Abstract][Full Text] [Related]
18. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
Kanis M; Kesterson JP; Lele S
Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
[TBL] [Abstract][Full Text] [Related]
19. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
Von Moos R; Cathomas R
Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
[No Abstract] [Full Text] [Related]
20. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
